Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating Expenses:
Research and development	$ 1,818	$ 2,988	$ 3,317	$ 5,026
General and administrative	2,474	2,358	5,032	4,912
Total operating expenses	4,292	5,346	8,349	9,938
Operating loss	(4,292)	(5,346)	(8,349)	(9,938)
Other income:
Investment income, net	22	209	93	436
Total other income	22	209	93	436
Loss before benefit from income taxes and noncontrolling interests	(4,270)	(5,137)	(8,256)	(9,502)
Benefit from income taxes	(10,872)	0	(10,872)	0
Net income (loss)	6,602	(5,137)	2,616	(9,502)
Less - net income attributable to noncontrolling interests	4	3	8	5
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ 6,598	$ (5,140)	$ 2,608	$ (9,507)
Basic and diluted income (loss) per share
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ 0.50	$ (0.49)	$ 0.22	$ (0.93)
Weighted average common shares outstanding
Basic and diluted shares	13,151	10,393	11,880	10,211